Pediatric Vouchers Could Limit Adult Rare Disease Development, US FDA Says
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is continuing to lobby criticisms at the rare pediatric disease priority review voucher program even as it gains in popularity.